NEW YORK (GenomeWeb) — Quidel said today that it has received de novo clearance from the US Food and Drug Administration to market its Lyra Direct Strep multiplex real-time PCR assay.
The new test detects and differentiates between pyogenic Group A and pyogenic C or G streptococcal throat infections.